Opioid-class REMS unlikely to halt abuse; U.S. trade office IDs Brazil, China, India among counterfeit hot spots;

> Opioid REMS implementation costs will be passed along to consumers and third-party payers, despite their "unlikely" ability to reduce or mitigate opioid abuse. Article

> The Office of the United States Trade Representative cites Brazil, China, India, Indonesia and Russia as areas of concern for the proliferation of counterfeit drugs. Article

> Catalent has named Barry Russell president of its commercial packaging group. Release

> Big-three drug distributor McKesson's yearly outlook beat Wall Street's estimate. Item

> Increasing challenges balanced by sound fundamentals and healthy growth prospects will yield stable credit risk profiles for Indian pharma companies in the international markets, says CRISIL Ratings. Article

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

Roche will spend $500 million for a new global manufacturing logistics hub in Canada that will eventually employ 500 workers in Ontario.

Fledgling Indiana CDMO Incog BioPharma Services is shelling out $60 million to get its first manufacturing facility off the ground.